Loading stock data…
$18.62-0.79 (-4.07%)
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACADIA Pharmaceuticals Inc. in the Healthcare sector is trading at $18.62 with a market capitalization of $4.8B. Wall Street consensus targets $30.58 (19 analysts), implying a +64.2% move over the next 12 months. The stock is currently near its 52-week low of $18.39, remaining 22.8% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 5 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $307.96M↑ | $268.06M↓ | $283.99M↑ | $278.63M↑ | $264.57M |
| Gross Profit | $279.64M↑ | $243.27M↓ | $257.76M↑ | $256.99M↑ | $243.83M |
| Operating Income | $37.84M↑ | -$4.62M↓ | $17.39M↓ | $35.76M↑ | $32.37M |
| Net Income | $31.50M↑ | $3.64M↓ | $273.57M↑ | $71.78M↑ | $26.67M |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agon...